- Home
- MCRB vs RSSS Comparison
MCRB vs RSSS Comparison
Compare MCRB & RSSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- RSSS
- Stock Information
- Founded
- MCRB 2010
- RSSS 2006
- Country
- MCRB United States
- RSSS United States
- Employees
- MCRB N/A
- RSSS N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- RSSS Business Services
- Sector
- MCRB Health Care
- RSSS Consumer Discretionary
- Exchange
- MCRB Nasdaq
- RSSS Nasdaq
- Market Cap
- MCRB 103.7M
- RSSS 90.6M
- IPO Year
- MCRB 2015
- RSSS N/A
- Fundamental
- Price
- MCRB $12.09
- RSSS $2.95
- Analyst Decision
- MCRB Hold
- RSSS
- Analyst Count
- MCRB 4
- RSSS 0
- Target Price
- MCRB $73.67
- RSSS N/A
- AVG Volume (30 Days)
- MCRB 107.4K
- RSSS 44.9K
- Earning Date
- MCRB 08-12-2025
- RSSS 05-08-2025
- Dividend Yield
- MCRB N/A
- RSSS N/A
- EPS Growth
- MCRB N/A
- RSSS N/A
- EPS
- MCRB 8.98
- RSSS N/A
- Revenue
- MCRB N/A
- RSSS $48,753,578.00
- Revenue This Year
- MCRB N/A
- RSSS $12.42
- Revenue Next Year
- MCRB N/A
- RSSS $7.47
- P/E Ratio
- MCRB $1.42
- RSSS N/A
- Revenue Growth
- MCRB N/A
- RSSS 14.85
- 52 Week Low
- MCRB $6.53
- RSSS $2.32
- 52 Week High
- MCRB $30.60
- RSSS $4.24
- Technical
- Relative Strength Index (RSI)
- MCRB 66.74
- RSSS 54.66
- Support Level
- MCRB $10.67
- RSSS $2.94
- Resistance Level
- MCRB $12.84
- RSSS $3.10
- Average True Range (ATR)
- MCRB 1.09
- RSSS 0.09
- MACD
- MCRB 0.34
- RSSS 0.02
- Stochastic Oscillator
- MCRB 85.98
- RSSS 62.45
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About RSSS Research Solutions Inc
Research Solutions Inc is a holding company. The company provides a cloud-based SaaS research intelligence platform consisting of proprietary software and Internet-based interfaces. Its platform also allows customers to find and download digital versions of STM articles. Platforms and Transactions are packaged as a single solution that enables life science and other research-intensive organizations to speed up research and development activities. The company platform allows customers to initiate orders, manage transactions, automate authentication, obtain reports, and connect seamlessly to corporate intranets.